To date, telemedicine has been largely focused on "first contact visits." Psoriasis presents unique challenges, including the need for long-term management. Telemedicine offers opportunities to develop novel approaches such as exploring artificial intelligence (AI) solutions and the personal management of psoriasis care. IPC convened a working group to establish a road map for how IPC can aid the development and implementation of telemedicine focused on psoriasis diagnosis and management. The telemedicine working group, chaired by Alexander Navarrini and co-chaired by Joel Gelfand, is in the process of developing a consensus statement regarding telemedicine in psoriasis management.
Chair Alexander Navarini Switzerland
Co-chair Joel Gelfand USA
Working Group Members
April Armstrong, USA Andrea Chiricozzi, Italy Vahid Diamei, Switzerland Mohamed El-Komy, Egypt Christophe Hsu, Switzerland Peter van de Kerkhof, Netherlands, IPC CMO Christy Langan, USA, IPC CEO Staff liaison: Tina Burke, USA
About IPC Our Strategic Plan IPC's plan for advancing knowledge and enhancing care for patients with psoriasis. READ MORE
IPC's plan for advancing knowledge and enhancing care for patients with psoriasis.
Latest news Video Series on IPC’s Psoriasis Severity ReclassificationMarch 30, 2021Learn how psoriasis severity is currently measured and why a change is necessary, how IPC organized the Delphi process that was used to redefine severity classification, implications and effects the output has on psoriasis treatment providers and psoriasis patients, and ultimately how patients will benefit from this endeavor. Janssen Phase-3 TREMFYA® Clinical TrialMarch 29, 2021Janssen Pharmaceutical Companies of Johnson & Johnson published the long-term data of the third phase of the DISCOVER-2a study. Sun Pharma Phase-3 ILUMYA® Clinical TrialMarch 28, 2021Sun Pharmaceutical Industries Inc. announces results from their five-year Phase-3 efficacy and safety clinical trial for ILUMYA®(tildrakizumab-asmn) based on a pooled analysis of the ReSURFACE 1 and ReSURFACE 2 extension. Update on PsoProtect Registry DataMarch 17, 2021Update on the PsoProtect Registry. PsoProtect is a global registry for clinicians to report outcomes of COVID-19 in individuals with psoriasis. Data set currently includes 1002 cases. More News